References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2023-2-93-99

mrj-1416

Research Article

ОБЗОРЫ

REVIEWS

Факторы риска тромбозов при АНЦА-ассоциированных васкулитах

Thrombosis risk factors in ANCA-associated vasculitis

https://orcid.org/0000-0001-8864-7623

Харламова

Е. Н.

Kharlamova

E. N.

Евгения Николаевна Харламова

115522, Москва, Каширское шоссе, 34А

Evgenia Nikolaevna Kharlamova -Department of Rheumatology RMACPE.

134A, Kashirskoe Shosse, Moscow 115522

evgenya.harlamova@yandex.ru

https://orcid.org/0000-0003-3552-2522

Решетняк

Т. М.

Reshetnyak

T. M.

кафедра ревматологии РМАНПО.

115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

Department of Rheumatology RMACPE

34A, Kashirskoe Shosse, Moscow 115522; 22/1, Barrikadnaya Street, Build. 1, Moscow 125993

https://orcid.org/0000-0001-9933-5350

Тарасова

Г. М.

Tarasova

G. M.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Federation

2023

22042023

1729399

2023

Харламова Е.Н., Решетняк Т.М., Тарасова Г.М.

Kharlamova E.N., Reshetnyak T.M., Tarasova G.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/1416

Представлен обзор современных данных о факторах риска артериовенозных тромбозов при ассоциированных с антинейтрофильными цитоплазматическими антителами васкулитах (ААВ). Тромботические осложнения относятся к числу самых частых прогностически неблагоприятных факторов при ААВ. В целом пациенты с ААВ подвергаются большему риску смертности от сердечно-сосудистых событий в сравнении с общей популяцией и с больными, имеющими другие формы системного васкулита. Понимание механизмов тромбообразования, а также патогенных факторов, вызывающих повышенный риск артериальных и венозных тромбозов при ААВ, может способствовать улучшению качества ведения этих пациентов. Поэтому вопрос о необходимости первичной и вторичной профилактики тромбозов при ААВ имеет большое практическое значение. Представленные в обзоре материалы указывают на необходимость оценки вероятности тромбоза у больных ААВ с учетом факторов риска, а также влияния самого заболевания и проводимой терапии. Оценка риска тромбозов (как венозных, так и артериальных) необходима для своевременного назначения адекватного профилактического лечения тромботических осложнений при ААВ.

The article presents a review of current data on arteriovenous thrombosis risk factors in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Thrombotic complications are among the most frequent prognostically unfavorable factors in AAV. In general, patients with AAV are at greater risk of mortality from cardiovascular events compared with the general population and patients with other forms of systemic vasculitis. Understanding the mechanisms of thrombosis, as well as pathogenic factors that cause an increased risk of arterial and venous thrombosis in AAV, can improve the quality of management of these patients. Therefore, the question of the need for primary and secondary prevention of thrombosis in AAV is of great practical importance. The presented data show the need to estimate the probability of thrombosis in patients with AAV, taking into account risk factors, as well as the influence of the disease itself and ongoing therapy. Assessment of the risk of thrombosis (both venous and arterial) is necessary for the timely administration of adequate preventive treatment of thrombotic complications in AAV.

АНЦА-ассоциированные васкулитытромбозтромбоз глубоких вентромбоэмболия легочной артерииартериальный тромбоз

ANCA-associated vasculitisthrombosisdeep vein thrombosispulmonary embolismarterial thrombosis

References1

Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715.

Бекетова ТВ, Насонов ЕЛ. Современные представления о классификации и лечении системных васкулитов, ассоциированных с антинейтрофильными цитоплазматическими антителами: итоги 2011 г. Терапевтический архив. 2012;84(5):68-74.

Beketova TV, Nasonov EL. Current trends in classification and treatment of systemic vasculitis associated with anti-neutrophilic cytoplasmic antibodies: results of 2011. Terapevticheskii arkhiv. 2012;84(5):68-74. (In Russ.).

Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2020 Jan;75(1):124-37. doi: 10.1053/j.ajkd.2019.04.031.

Wolff SM, Fauci AS, Horn RG, Dale DC. Wegener's granulomatosis. Ann Intern Med. 1974 Oct;81(4):513-25. doi: 10.7326/00034819-81-4-513.

Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.

Misra DP, Naidu GSRSNK, Sharma A. Recent advances in the management of antineutrophil cytoplasmic antibody-associated vasculitis. Indian J Rheumatol. 2019;14:218-28. doi: 10.4103/injr.injr_141_19.

Арсеньев ЕВ, Тополянская СВ. Тромботические и тромбоэмболические осложнения при системных васкулитах. Клиницист. 2017;11(2):24-32.

Arsen'ev EV, Topolyanskaya SV. Thrombotic and thromboembolic complications in systemic vasculitis. Klinitsist. 2017;11(2):24-32. (In Russ.).

Morgan MD, Turnbull J, Selamet U, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matchedpair cohort study. Arthritis Rheum. 2009 Nov; 60(11):3493-500. doi: 10.1002/art.24957.

Phillippe HM. Overview of venous thromboembolism. Am J Manag Care. 2017 Dec; 23(20 Suppl):S376-S382.

Hansrivijit P, Trongtorsak A, Gadhiya KP, et al. Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression. Clin Rheumatol. 2021 Jul;40(7):2843-53. doi: 10.1007/s10067-021-05589-8.

Liapi M, Jayne D, Merkel PA, et al. Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study. Rheumatology (Oxford). 2021 Oct 2; 60(10):4616-23. doi: 10.1093/rheumatology/keab057.

Moiseev S, Kronbichler A, Makarov E, et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology (Oxford). 2021 Oct 2;60(10):4654-61. doi: 10.1093/rheumatology/keab071.

Isaacs B, Gapud EJ, Antiochos B, et al. Venous Thrombotic Events in ANCA-Associated Vasculitis: Incidence and Risk Factors. Kidney360. 2020 Mar 3;1(4):258-62. doi: 10.34067/KID.0000572019.

Kronbichler A, Leierer J, Shin JI, et al. Association of pulmonary hemorrhage, positive proteinase 3, and urinary red blood cell casts with venous thromboembolism in antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheumatol. 2019 Nov;71(11): 1888-93. doi: 10.1002/art.41017.

Kang A, Antonelou M, Wong NL, et al. High incidence of arterial and venous thrombosis in antineutrophil cytoplasmic antibodyassociated vasculitis. J Rheumatol. 2019 Mar; 46(3):285-93. doi: 10.3899/jrheum.170896. Epub 2018 Nov 1.

Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ. 2012 Jan 25;344: d8059. doi: 10.1136/bmj.d8059.

Berti A, Matteson EL, Crowson CS, et al. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20-year population-based cohort study. Mayo Clin Proc. 2018 May;93(5):597-606. doi: 10.1016/j.mayocp.2018.02.010.

Suppiah R, Judge A, Batra R, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011 Apr;63(4):588-96. doi: 10.1002/acr.20433.

Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016 Jan;41(1): 3-14. doi: 10.1007/s11239-015-1311-6.

Yang JJ, Preston GA, Pendergraft WF, et al. Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants. Am J Pathol. 2001 Feb;158(2):581-92. doi: 10.1016/S00029440(10)64000-X.

Gutmann C, Siow R, Gwozdz AM, et al. Reactive Oxygen Species in Venous Thrombosis. Int J Mol Sci. 2020 Mar 11;21(6):1918. doi: 10.3390/ijms21061918.

Kettritz R. With complements from ANCA mice. J Am Soc Nephrol. 2014 Feb; 25(2):207-9. doi: 10.1681/ASN.2013101043.

Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009 Apr;68(4):564-7. doi: 10.1136/ard.2008.099051.

Zhang Z, Huang W, Ren F, et al. Analysis of Risk Factors and the Establishment of a Predictive Model for Thrombosis in Patients with Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis. Int J Gen Med. 2022 Nov 7;15:8071-9. doi: 10.2147/IJGM.S384624.

Rao AN, Kazzaz NM, Knight JS. Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases? World J Cardiol. 2015 Dec 26;7(12): 829-42. doi: 10.4330/wjc.v7.i12.829.

Antovic A, Svensson E, Lövström B, et al. Venous thromboembolism in anti-neutrophil cytoplasmic antibody-associated vasculitis: an underlying prothrombotic condition? Rheumatol Adv Pract. 2020 Oct 16;4(2):rkaa056. doi: 10.1093/rap/rkaa056.

Novikov P, Makarov E, Moiseev S, et al. Venous thromboembolic events in systemic vasculitis. Ann Rheum Dis. 2015 Mar;74(3): e27. doi: 10.1136/annrheumdis-2014-206849.

Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010 Nov;8(11): 2450-7. doi: 10.1111/j.1538-7836.2010.04044.x.

Боброва ЛА, Козловская НЛ. Тромбоэмболические осложнения нефротического синдрома. Терапевтический архив. 2020;92(6):105-16.

Bobrova LA, Kozlovskaya NL. Thromboembolic complications in nephrotic syndrome. Terapevticheskii arkhiv. 2020;92(6):105-16. (In Russ.).

Козловская НЛ. Низкомолекулярные гепарины в практике нефролога. Клиническая нефрология. 2011;1:15-22.

Kozlovskaya NL. Low molecular weight heparins in nephrologists practice. Clinical Nephrology. 2011;1:15-22 (In Russ.).

Семенкова ЕН. Системные васкулиты. Москва: Медицина;1988. 238 с.

Semenkova EN. Sistemnye vaskulity [Systemic vasculitides]. Moscow: Meditsina; 1988. 238 p..

Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003 Apr;41(4):776-84. doi: 10.1016/s02726386(03)00025-8.

Sinico RA, Di Toma L, Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev. 2013 Feb;12(4):477-82. doi: 10.1016/j.autrev.2012.08.006.

Berti A, Cornec-Le Gall E, Cornec D, et al. Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol Dial Transplant. 2019 Sep 1;34(9): 1508-17. doi: 10.1093/ndt/gfy250.

Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998 May; 9(5):842-52. doi: 10.1681/ASN.V95842.

Jennette JC, Nachman PH. ANCA Glomerulonephritis and Vasculitis. Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1680-91. doi: 10.2215/CJN.02500317.

Al-Azzawi HF, Obi OC, Safi J, Song M. Nephrotic syndrome-induced thromboembolism in adults. Int J Crit Illn Inj Sci. 2016 AprJun;6(2):85-8. doi: 10.4103/2229-5151.183019.

Rydzewski A, My liwiec M, Soszka J. Concentration of three thrombin inhibitors in the nephrotic syndrome in adults. Nephron. 1986;42(3):200-3. doi: 10.1159/000183667.

Rankin AJ, McQuarrie EP, Fox JG, et al. Venous Thromboembolism in Primary Nephrotic Syndrome – Is the Risk High Enough to Justify Prophylactic Anticoagulation? Nephron. 2017;135(1):39-45. doi: 10.1159/000448628.

Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012 Jan; 81(2):190-5. doi: 10.1038/ki.2011.312.

Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012 Oct;64(10):3452-62. doi: 10.1002/art.34562.

Lin R, McDonald G, Jolly T, et al. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Kidney Int Rep. 2019 Dec 12;5(4):435-47. doi: 10.1016/j.ekir.2019.12.001.

Jørgensen KA, Stoffersen E. On the inhibitory effect of albumin on platelet aggregation. Thromb Res. 1980 Jan 1-15;17(1-2):13-8. doi: 10.1016/0049-3848(80)90289-3. PMID: 6990546.

Mendoza CE, Brant EJ, McDermott ML, et al. Elevated Microparticle Tissue Factor Activity Differentiates Patients With Venous Thromboembolism in Anti-neutrophil Cytoplasmic Autoantibody Vasculitis. Kidney Int Rep. 2019 Jul 13;4(11):1617-29. doi: 10.1016/j.ekir.2019.07.006.

Kanfer A. Coagulation factors in nephrotic syndrome. Am J Nephrol. 1990;10 Suppl 1:63-8. doi: 10.1159/000168196.

Ovali E, Ratip S, Ozmenoglu M, et al. Large volume donor plasmapheresis in inherited thrombophilia implicated in arterial thrombosis. Transfus Apher Sci. 2003 Jun; 28(3):201-6. doi: 10.1016/S1473-0502(03)00054-5.

Jaldo Rodriguez MT, Borrego Utiel FJ, Borrego Hinojosa J, Perez Del Barrio MP. Development of deep vein thrombosis during treatment with plasmapheresis. Nefrologia. 2017 Mar-Apr;37(2):219-20. doi: 10.1016/j.nefro.2016.09.014.

Kronbichler A, Leierer J, Leierer G, et al. Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibodyassociated vasculitides. Rheumatology (Oxford). 2017 May 1;56(5):704-8. doi: 10.1093/rheumatology/kew465.

Petermann Smits DR, Wilde B, Kianersi Adegani M, et al. Metabolic syndrome in ANCA-associated vasculitis. Rheumatology (Oxford). 2013 Jan;52(1):197-203. doi: 10.1093/rheumatology/kes345.

Nørgaard I, Nielsen SF, Nordestgaard BG. Complement C3 and High Risk of Venous Thromboembolism: 80517 Individuals from the Copenhagen General Population Study. Clin Chem. 2016 Mar;62(3):525-34. doi: 10.1373/clinchem.2015.251314.

Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement – their role in inflammation. Semin Immunopathol. 2012 Jan;34(1):151-65. doi: 10.1007/s00281-011-0280-x.

Kambas K, Chrysanthopoulou A, Vassilopoulos D, et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis. 2014 Oct;73(10):1854-63. doi: 10.1136/annrheumdis-2013-203430.

Сатыбалдыев АМ. Глюкокортикоидный синдром Кушинга в практике ревматолога (обзор литературы). Современная ревматология. 2013;7(4):78-84. doi: 10.14412/1996-7012-2013-2443.

Satybaldyev AM. Cushing’s glucocorticoid syndrome in the practice of a rheumatologist (A review of literature). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(4):78-84. (In Russ.). doi: 10.14412/1996-7012-2013-2443.

Higgins PD, Skup M, Mulani PM, et al. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015 Feb;13(2):316-21. doi: 10.1016/j.cgh.2014.07.017.

Johannesdottir SA, Horvath-Puhу E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013 May 13;173(9):743-52. doi: 10.1001/jamainternmed.2013.122.

Stuijver DJF, Majoor CJ, van Zaane B, et al. Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest. 2013 May;143(5): 1337-42. doi: 10.1378/chest.12-1446.

Walsh M, Merkel PA, Peh CA, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020 Feb 13;382(7):622-31. doi: 10.1056/NEJMoa1803537.

Бекетова ТВ. Перспективные направления терапии системных васкулитов: в фокусе авакопан, пероральный селективный ингибитор С5а рецептора. Клиническая фармакология и терапия. 2019; 28(1):75-9.

Beketova TV. New treatments for systemic vasculitis therapy: focus on avacopan, an oral selective 5a receptor inhibitor. Klinicheskaya farmakologiya i terapiya. 2019;28(1):75-9. (In Russ.).

Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021 Feb 18;384(7): 599-609. doi: 10.1056/NEJMoa2023386.

Huang YM, Wang H, Wang C, et al. Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps. Arthritis Rheumatol. 2015 Oct;67(10):2780-90. doi: 10.1002/art.39239.

Faurschou M, Mellemkjaer L, Sorensen IJ, et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum. 2009 Apr;60(4):1187-92. doi: 10.1002/art.24386.

Lee S, Shafe AC, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database. BMJ Open. 2011 Jan 1;1(2):e000269. doi: 10.1136/bmjopen-2011-000269.

Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012 Sep 1;380(9844):807-14. doi: 10.1016/S0140-6736(12)60572-8.

The authors declare that there are no conflicts of interest present.